Samjin Pharmaceutical Selected for National Project on Preclinical and Clinical Model Development for 'K-AI New Drug'

Participation as a Joint Research Institute in a 37.1 Billion Won Project

Samjin Pharmaceutical announced on November 12 that it will participate as a joint research institute in the government-led national project for artificial intelligence (AI)-based new drug development. The company aims to accelerate clinical entry by linking preclinical and clinical data using AI, and to establish an end-to-end new drug development ecosystem leveraging AI technology.

Samjin Pharmaceutical Research Center located in Magok-dong, Gangseo-gu, Seoul. Samjin Pharmaceutical

The “2025 K-AI New Drug Development Preclinical and Clinical Model Development Project,” overseen by the Ministry of Health and Welfare, is a large-scale national research and development (R&D) initiative with a total budget of 37.1 billion won. For the first time in Korea, it will build an AI-based platform for designing and supporting clinical trials in new drug development. The project is managed by the AI New Drug Research Institute of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association, with major domestic industry, academia, research, and medical institutions participating together.

Samjin Pharmaceutical will participate as a joint institution in the “Translational Research AI Software Development” sector, led by Seoul National University Hospital. The company will be responsible for ▲ the production and standardization of preclinical multimodal data ▲ the application and validation of AI-based clinical trial design ▲ and the demonstration of IND approval.

Specifically, Samjin Pharmaceutical will provide accumulated preclinical data in various fields such as oncology and metabolic diseases, and will take on the role of building high-quality preclinical-clinical multimodal datasets. In addition, by utilizing diverse experimental data generated at the preclinical stage, the company plans to enhance the quality of AI model training and apply these AI models to the actual design of candidate clinical trials, focusing on improving model accuracy based on validation results.

Through this project, Samjin Pharmaceutical aims to establish a “data feedback research system” in which AI prediction and experimental validation are continuously cycled, thereby narrowing the data gap between preclinical and clinical stages and significantly increasing the likelihood of clinical trial success. The company’s goal is to contribute to tangible achievements in domestic AI-driven new drug development.

Lee Sumin, Head of the Samjin Pharmaceutical Research Center, stated, “This K-AI project will serve as a turning point, expanding prediction-centered AI drug development into the actual clinical design stage.”